Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH -0.64%88 3-Year EBITDA Growth Rate is 22.10% as of Mar. 2026, which is 107% above its 10-year median of 10.70. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.78 (Fairly Valued). The stock has 2 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 68.11% on this metric.
During the past 12 months, Fisher & Paykel Healthcare's average EBITDA Per Share Growth Rate was 22.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -0.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fisher & Paykel Healthcare was 51.70% per year. The lowest was -23.30% per year. And the median was 10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Fisher & Paykel Healthcare 3-Year EBITDA Growth Rate Related Terms
ASX:FPH vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.10% mean?
Fisher & Paykel Healthcare (ASX:FPH) has a 3-Year EBITDA Growth Rate of 22.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fisher & Paykel Healthcare and its competitors. This is 107% above median its historical median of 10.70. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #221 out of 693 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is Fisher & Paykel Healthcare's 3-Year EBITDA Growth Rate too high?
Fisher & Paykel Healthcare's current 3-Year EBITDA Growth Rate of 22.10% is 107% above median its 10-year median of 10.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Fisher & Paykel Healthcare's value of 22.10% is 172.8% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #221 out of 693 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #221 out of 693 companies for 3-Year EBITDA Growth Rate. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Fisher & Paykel Healthcare's value of 22.10% is 172.8% above this benchmark. While the company's 10-year median is 10.70 vs. the industry median of 8.10, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current 3-Year EBITDA Growth Rate of 22.10% is 172.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current 3-Year EBITDA Growth Rate is 22.10%, which is 107% above median its own 10-year median of 10.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.78, compared to a current price of A$34.02 — trading 7.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.10%, which is 107% above median its 10-year median of 10.70 and 172.8% above the Medical Devices & Instruments industry median of 8.10. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current 3-Year EBITDA Growth Rate is 22.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$34.02 is trading 7.5% below its estimated GF Value™ of A$36.78.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
3-Year EBITDA Growth Rate: 22.10% (107% above median its 10-year median of 10.70)
GF Value™: A$36.78 vs. price of A$34.02 (7.5% below fair value)
Industry Position: 172.8% above the Medical Devices & Instruments median (#221 of 693)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
